Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma
复制标题
DOI：
10.1002/ajh.23274
复制
发表时间：
2012-10-01
影响因子：
12.8
通讯作者：
de Souza, Carmino A.
中科院分区：
文献类型：
--
作者：
Maiolino, Angelo;Hungria, Vania T. M.;de Souza, Carmino A.
尽管干细胞移植（SCT）治疗多发性骨髓瘤（MM）的反应良好，但大多数患者复发或未达到完全缓解，这表明需要额外的治疗。我们评估了沙利度胺对未经治疗的MM患者SCT后维持治疗的影响。
Despite the good response of stem cell transplant (SCT) in the treatment of multiple myeloma (MM), most patients relapse or do not achieve complete remission, suggesting that additional treatment is needed. We assessed the impact of thalidomide in maintenance after SCT in untreated patients with MM. A hundred and eight patients (